File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Cytoplasmic CXCR4 high-expression exhibits distinct poor clinicopathological characteristics and predicts poor prognosis in triple-negative breast cancer

TitleCytoplasmic CXCR4 high-expression exhibits distinct poor clinicopathological characteristics and predicts poor prognosis in triple-negative breast cancer
Authors
KeywordsChemokine (C-X-C motif) ligand 12 (CXCL12)
CXC chemokine receptor types 4 (CXCR4)
HER2-neu
HER2-positive breast cancer
Luminal breast cancer
Triple negative breast cancer
Visceral organ specificmetastases
Issue Date2013
PublisherBentham Science Publishers Ltd. The Journal's web site is located at http://www.bentham.org/cmm/index.htm
Citation
Current Molecular Medicine, 2013, v. 13 n. 3, p. 410-416 How to Cite?
AbstractCXC chemokine receptor type 4 (CXCR4) plays a prominent role in cancer progression and metastasis. However, its association with breast cancer subtypes is still unknown. In the current study, we analyzed the expression level and the cellular location of CXCR4 in 175 cases of human breast tumors, including 75 cases of triple-negative breast cancers (TNBCs), 41 cases of luminal-subtypes and 60 cases of HER2-positive breast cancers by using immmunohistochemistry (IHC). We found that CXCR4 was expressed more frequently in the TNBCs than in other subtypes (71% for TNBC vs 44% for HER2-positive and 37% for luminal subtype, p < 0.001). In the TNBC group, CXCR4 positive patients have a significantly higher rate of visceral metastasis (liver, lung and brain). The expression level of CXCR4 is also significantly related to tumor size, advanced TNM stage, shorter overall- and disease-free survival. However, in luminal or HER2-positive breast cancer groups, CXCR4 is not correlated with such clinico-pathological characteristics and survival. Taken together, our data indicate that CXCR4 might exert its function exclusively in TNBC patients, suggesting that targeting CXCR4 might be an effective therapy for TNBC patients.
Persistent Identifierhttp://hdl.handle.net/10722/186465
ISSN
2023 Impact Factor: 2.2
2023 SCImago Journal Rankings: 0.531
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChen, HW-
dc.contributor.authorDu, CW-
dc.contributor.authorWei, XL-
dc.contributor.authorKhoo, US-
dc.contributor.authorZhang, GJ-
dc.date.accessioned2013-08-20T12:09:14Z-
dc.date.available2013-08-20T12:09:14Z-
dc.date.issued2013-
dc.identifier.citationCurrent Molecular Medicine, 2013, v. 13 n. 3, p. 410-416-
dc.identifier.issn1566-5240-
dc.identifier.urihttp://hdl.handle.net/10722/186465-
dc.description.abstractCXC chemokine receptor type 4 (CXCR4) plays a prominent role in cancer progression and metastasis. However, its association with breast cancer subtypes is still unknown. In the current study, we analyzed the expression level and the cellular location of CXCR4 in 175 cases of human breast tumors, including 75 cases of triple-negative breast cancers (TNBCs), 41 cases of luminal-subtypes and 60 cases of HER2-positive breast cancers by using immmunohistochemistry (IHC). We found that CXCR4 was expressed more frequently in the TNBCs than in other subtypes (71% for TNBC vs 44% for HER2-positive and 37% for luminal subtype, p < 0.001). In the TNBC group, CXCR4 positive patients have a significantly higher rate of visceral metastasis (liver, lung and brain). The expression level of CXCR4 is also significantly related to tumor size, advanced TNM stage, shorter overall- and disease-free survival. However, in luminal or HER2-positive breast cancer groups, CXCR4 is not correlated with such clinico-pathological characteristics and survival. Taken together, our data indicate that CXCR4 might exert its function exclusively in TNBC patients, suggesting that targeting CXCR4 might be an effective therapy for TNBC patients.-
dc.languageeng-
dc.publisherBentham Science Publishers Ltd. The Journal's web site is located at http://www.bentham.org/cmm/index.htm-
dc.relation.ispartofCurrent Molecular Medicine-
dc.subjectChemokine (C-X-C motif) ligand 12 (CXCL12)-
dc.subjectCXC chemokine receptor types 4 (CXCR4)-
dc.subjectHER2-neu-
dc.subjectHER2-positive breast cancer-
dc.subjectLuminal breast cancer-
dc.subjectTriple negative breast cancer-
dc.subjectVisceral organ specificmetastases-
dc.titleCytoplasmic CXCR4 high-expression exhibits distinct poor clinicopathological characteristics and predicts poor prognosis in triple-negative breast cancer-
dc.typeArticle-
dc.identifier.emailKhoo, US: uskhoo@hku.hk-
dc.identifier.authorityKhoo, US=rp00362-
dc.identifier.doi10.2174/156652413805076803-
dc.identifier.pmid23331013-
dc.identifier.scopuseid_2-s2.0-84877757306-
dc.identifier.hkuros220091-
dc.identifier.volume13-
dc.identifier.issue3-
dc.identifier.spage410-
dc.identifier.epage416-
dc.identifier.isiWOS:000317116100010-
dc.publisher.placeNetherlands-
dc.identifier.issnl1566-5240-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats